Nephros 510(k) woes
This article was originally published in The Gray Sheet
Executive Summary
Kidney dialysis product maker plans to meet with FDA to discuss next steps after the agency rejected a 510(k) pre-market submission for the firm's hemodiafiltration (HDF) system, designed to improve quality of life in end-stage renal disease (ESRD) patients. FDA sent a not-substantially-equivalent decision letter to the firm June 30, but Nephros says it had no opportunity to address the agency's questions before the decision was rendered. "We feel that the issues raised in the current letter are addressable," the company said July 7. According to the firm, the HDF system removes harmful substances from patients' blood "more effectively, and with greater capacity, than existing ESRD treatment methods." After meeting with FDA, Nephros plans to file a new 510(k) or appeal the current decision
You may also be interested in...
News In Brief
Joint Commission urges caution in imaging
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.